Table 2.
Clinical and cost-effectiveness outcomes
| Health outcome | Afatinib | Erlotinib | Difference |
|---|---|---|---|
| Progression-free survival time (months) | 5.05 | 3.85 | 1.2 |
| Post-progression survival time (months) | 6.84 | 6.12 | 0.72 |
| Life expectancy (years) | 0.94 | 0.78 | 0.16 |
| Quality-adjusted life expectancy (QALY) | 0.567 | 0.473 | 0.094 |
| Total costs (EUR) | 12,364 | 9,510 | 2,854 |
| ICER based on life expectancy | EUR18,568 per LY gained | ||
| ICER based on quality-adjusted life expectancy | EUR30,277 per QALY gained |
Abbreviations: ICER, incremental cost-effectiveness ratio; LY, life year; QALY, quality-adjusted life year.